–Clinilabs, a contract research organization that provides early-stage and specialty clinical drug development services to industry, announced today that they have been selected to conduct a Phase I clinical research study of an investigational medication for Rosacea.
According to Dr. Gary Zammit, President & CEO of Clinilabs, "The award of this project represents a significant achievement for the organization as it builds upon its experience as a specialty service provider to expand into new therapeutic areas." Zammit also notes that early phase development programs, regardless of the therapeutic area, deserve the attention of a focused group of experienced professionals who partner with sponsors for success.
Enrollment for this study is expected to begin in mid-September. Individuals in the New York City Metro area who demonstrate signs of facial redness, facial flushing, or bumps on the face, or who have been diagnosed with the condition, can contact our dedicated recruitment staff at 212-994-4567 to prequalify. Additional information may also be found by visiting
www.clinilabs.com/volunteers.
Clinilabs is a contract research organization (CRO) that provides early-phase and specialty clinical drug development services to industry. We offer teams, processes, and technology solutions that are designed to serve single center and multicenter early-phase studies – services that can be scaled as needed to meet the requirements of any clinical development program. For more information, visit www.clinilabs.com.
Jeanine Estrada
Clinilabs Inc.
Tel. 646.450.2215
jestrada@clinilabs.com
|
